- Conditions
- Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus, Mixed Connective Tissue Disease, Juvenile Ankylosing Spondylitis, Juvenile Dermatomyositis, Localized Scleroderma, Systemic Sclerosis, Vasculitis, Sarcoid, Fibromyalgia, Primary, Auto-inflammatory Disease, Idiopathic Uveitis Idiopathic
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- Not listed
- Enrollment
- 9,587 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 6,311
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diagnosis of Melanoma
- Interventions
- Autonomic Function Tests, supine and standing catecholamines
- Behavioral · Other
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Primary Biliary Cholangitis
- Interventions
- Baricitinib, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 10
- States / cities
- Coronado, California • Sacramento, California • Aurora, Colorado + 7 more
- Conditions
- Tooth Loss
- Interventions
- Osseodensification Densah Bur
- Device
- Lead sponsor
- Jackson Implant Surgery
- Industry
- Eligibility
- 22 Years to 80 Years
- Enrollment
- 23 participants
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Jackson, Michigan
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- filgrastim, pegfilgrastim, docetaxel, trabectedin
- Biological · Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 37
- States / cities
- Burbank, California • Los Angeles, California • New Britain, Connecticut + 28 more
- Conditions
- Primary Immune Deficiency Disorders, Metabolic Disease
- Interventions
- Haploidentical Hematopoietic Cell Transplantation
- Biological
- Lead sponsor
- Johns Hopkins All Children's Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- St. Petersburg, Florida
- Conditions
- Primary Amyloidosis
- Interventions
- NEOD001
- Drug
- Lead sponsor
- Prothena Biosciences Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 7
- States / cities
- Palo Alto, California • Boston, Massachusetts • Detroit, Michigan + 3 more
- Conditions
- Glaucoma, Primary Open Angle
- Interventions
- oxygen inhalation, Adaptive optics imaging
- Other · Device
- Lead sponsor
- Food and Drug Administration (FDA)
- Federal
- Eligibility
- 21 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2028
- U.S. locations
- 1
- States / cities
- Silver Spring, Maryland
- Conditions
- Glaucoma
- Interventions
- Phacoemulsification with implantation of intraocular lens (CE-IOL) SENSIMED Triggerfish
- Device
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Reperfusion Injury, STEMI
- Interventions
- Bendavia (MTP-131), Placebo
- Drug
- Lead sponsor
- Stealth BioTherapeutics Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 3
- States / cities
- Port Orange, Florida • Detroit, Michigan • Omaha, Nebraska
- Conditions
- Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy, Parkinson Disease, Orthostatic Hypotension
- Interventions
- Droxidopa, Midodrine, Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Primary Biliary Cholangitis
- Interventions
- Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo
- Drug
- Lead sponsor
- Zydus Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 27 more
- Conditions
- Liver Cancer
- Interventions
- celecoxib, erlotinib hydrochloride, adjuvant therapy
- Drug · Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Opioid Use Disorder, Neonatal Abstinence Syndrome, Child Development, Child Abuse, Child Neglect
- Interventions
- RESPECT-Plus
- Behavioral
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- Up to 21 Days
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Interventions
- STRO-002, Bevacizumab
- Drug
- Lead sponsor
- Sutro Biopharma, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 6
- States / cities
- Tampa, Florida • Philadelphia, Pennsylvania • Nashville, Tennessee + 2 more
- Conditions
- Hematological Malignancies
- Interventions
- Tacrolimus and Thymoglobulin
- Drug
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Orthostatic Hypotension
- Interventions
- Inspiratory Threshold Device (Res-Q-Gard ITD), Sham Inspiratory Threshold Device
- Device
- Lead sponsor
- Alfredo Gamboa
- Other
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2022
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Multiple Chronic Conditions
- Interventions
- Patient Priorities Care
- Behavioral
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 66 Years and older
- Enrollment
- 264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Lakewood, Ohio
- Conditions
- Nausea and Vomiting, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Stage II Ovarian Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Undifferentiated Ovarian Carcinoma
- Interventions
- Adjuvant Therapy, Aprepitant, Carboplatin, Cisplatin, Dexamethasone, Granisetron Transdermal Patch, Management of Therapy Complications, Questionnaire Administration
- Procedure · Drug · Other
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 2
- States / cities
- Hinsdale, Illinois • Providence, Rhode Island
- Conditions
- Dementia
- Interventions
- Alianza Latina
- Combination Product
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 243 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Tobacco Dependence
- Interventions
- nicotine patch, nicotine lozenge, bupropion, patch + lozenge, bupropion + lozenge
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,346 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Ovarian Cancer, Chemotherapeutic Toxicity
- Interventions
- Fasting Mimicking Diet (Xentigen by L'Nutra), Carboplatin, Paclitaxel, Standard diet
- Dietary Supplement · Drug
- Lead sponsor
- Endeavor Health
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 1
- States / cities
- Evanston, Illinois
- Conditions
- Migraine
- Interventions
- Erenumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 42
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Fullerton, California + 38 more
- Conditions
- Prenatal Alcohol Exposure, Prenatal Tobacco Exposure, Prenatal Marijuana Exposure
- Interventions
- Computer tablet-delivered C4H, Person-delivered C4H, Brief Advice
- Behavioral
- Lead sponsor
- University of Texas at Austin
- Other
- Eligibility
- 18 Years to 44 Years · Female only
- Enrollment
- 219 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Austin, Texas